CHICAGOV. Craig Jordan, PhD,
has been named Diana, Princess of Wales, Professor of Cancer Research
at Northwestern University. Dr. Jordan, a native of the United
Kingdom, is professor of cancer pharmacology at Northwestern
University Medical School and director of the Lynn Sage Breast Cancer
Research program affiliated with the Robert H. Lurie Comprehensive
Cancer Center of Northwestern University.
The endowed chair was funded by a generous gift from Chicago
philanthropist Ann Lurie and named in memory of Princess Diana, who
visited Northwestern in 1996 as the keynote speaker in a major
symposium on breast cancer. Northwestern received approval of the
family of Princess Diana for naming the endowed chair in her honor.
Mrs. Lurie is a member of the University Board of Trustees. The
Robert H. Lurie Cancer Center was named in memory of Mrs. Luries
husband, a Chicago business leader and philanthropist who died of cancer.
Dr. Jordan, dubbed the father of tamoxifen, has devoted
his entire 30-year scientific career to the study of antiestrogens,
beginning with his dissertation on estrogen receptors.
When Dr. Jordan began his work on tamoxifen (Nolvadex), the drug was
considered nothing more than a failed contraceptive.
Dr. Jordan saw its potential in breast cancer and performed studies
showing that the agent prevented the growth of mammary tumors in
rodents. As Dr. Jordan predicted, tamoxifen was subsequently found to
prevent breast cancer recurrence and increase survival of breast
cancer patients. More recently, it has been shown to prevent the
development of breast cancer in high-risk women.
Dr. Jordan has been instrumental in guiding the clinical development
of tamoxifen and, more recently, raloxifene (Evista), an antiestrogen
used to prevent osteoporosis. He is medical director of the STAR
(Study of Tamoxifen and Raloxifene) clinical trial, comparing the two
agents for breast cancer prevention in postmenopausal women.